SAB Biotherapeutics, Inc. (SABS) Stock Forecast & Price Target

SAB Biotherapeutics, Inc. (SABS) has an ST Score of 54.7 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate SABS a Buy, with a price target of $11.33 (+293.4% vs the current price). Our ST Score grades it B- (54.7/100). The ST Score is a data-driven signal, not a recommendation.

Valuation C+, Profitability A, Financial Strength B+, Momentum C+, Growth C-, Forecast A.

SAB Biotherapeutics, Inc. (SABS) earns a valuation grade of C+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

SAB Biotherapeutics, Inc. (SABS) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

SAB Biotherapeutics, Inc. (SABS) earns a profitability grade of A, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

SAB Biotherapeutics, Inc. (SABS) earns a financial strength grade of B+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for SAB Biotherapeutics, Inc. (SABS) is $11.33 from 8 analysts, which is +293.4% versus the recent price of $2.88.

SAB Biotherapeutics, Inc. (SABS) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.